10.3389/fcvm.2021.668532 127 SielandJ.NiedererD.EngeroffT.VogtL.TroidlC.Schmitz-RixenT.et al (2022)
As always, individual preferences, goals, and medical guidance should dictate the choice between these peptides
The available evidence is older, limited, and inconsistent a combination that places DSIP firmly outside the category of established, approved therapeutics
10.1097/EJA.0000000000002069 [DOI] [PubMed] [Google Scholar] 44.Hulst AH, Polderman JAW, Siegelaar SE, van Raalte DH, DeVries JH, Preckel B et al (2021) Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus
doi: 10.1016/s0140-6736(05)79824-x
This helps defend against free-radical damage and soothe scalp inflammation